Cargando…

CT-guided percutaneous implantation of (125)I particles in treatment of early lung cancer

BACKGROUND: To analyze the efficacy of computed tomography (CT)-guided implantation of (125)I radioactive particles in treatment of early lung cancer. METHODS: Six patients were analyzed, including 4 squamous cell carcinoma, 1 adenocarcinoma, and 1 small cell lung cancer. TPS software was used to ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Dong-Yong, Lin, Yan-Ping, Xue, Cheng, Fan, Ji-Min, Wang, Yi, Cai, Chi, Song, Duan-Hong, Zeng, Yi-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656391/
https://www.ncbi.nlm.nih.gov/pubmed/33209432
http://dx.doi.org/10.21037/jtd-20-2666
_version_ 1783608373041692672
author Yang, Dong-Yong
Lin, Yan-Ping
Xue, Cheng
Fan, Ji-Min
Wang, Yi
Cai, Chi
Song, Duan-Hong
Zeng, Yi-Ming
author_facet Yang, Dong-Yong
Lin, Yan-Ping
Xue, Cheng
Fan, Ji-Min
Wang, Yi
Cai, Chi
Song, Duan-Hong
Zeng, Yi-Ming
author_sort Yang, Dong-Yong
collection PubMed
description BACKGROUND: To analyze the efficacy of computed tomography (CT)-guided implantation of (125)I radioactive particles in treatment of early lung cancer. METHODS: Six patients were analyzed, including 4 squamous cell carcinoma, 1 adenocarcinoma, and 1 small cell lung cancer. TPS software was used to calculate the therapeutic dose amount of particles implanted, and the spacing and distribution of seeds in the target area and adjacent tissues. Under the guidance of CT, 20–55 particles were implanted at each site, with the total number of radioactive particles being 226, the particle spacing being 0.5–1.0 cm, and the implantation being performed in accordance with the principle of uniform implantation. The patients were each followed up with repeated pulmonary CT scans at 1, 3, 6, 12, 18, 24, 30 and 36 months after the procedure. In accordance with the response evaluation criteria in solid tumors (RECIST), the following definitions for responses were used: complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD). RESULTS: There were 2 CRs and 4 PRs one month after procedure; six patients were followed up 3 months after procedure, including 2 CRs and 4 PRs; one patient was lost in follow-up, and 5 patients were followed up 6 months after procedure, including 3 CRs and 2 PRs; five patients were followed up 12 months after procedure, including 3 CRs, 1 PR and 1 PD. The single PD patient was again given CT-guided implantation of (125)I radioactive particles for the treatment of recurrent lesions. The pulmonary CT was repeated 6 months after procedure, and the response was evaluated as SD. Four patients were followed up 18 months after procedure, including 3 CRs and 1 PR; one patient was lost in follow-up and 3 patients were followed up 24 months after the procedure with the response being evaluated as CR for all of them; one patient was followed up 36 months after procedure, and the response was evaluated as PD. During the follow-up, no serious complications occurred in any of the patients. CONCLUSIONS: The preliminary clinical observation showed that (125)I radioactive particle implantation was a safe, reliable and effective therapeutic method for early lung cancer.
format Online
Article
Text
id pubmed-7656391
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-76563912020-11-17 CT-guided percutaneous implantation of (125)I particles in treatment of early lung cancer Yang, Dong-Yong Lin, Yan-Ping Xue, Cheng Fan, Ji-Min Wang, Yi Cai, Chi Song, Duan-Hong Zeng, Yi-Ming J Thorac Dis Original Article BACKGROUND: To analyze the efficacy of computed tomography (CT)-guided implantation of (125)I radioactive particles in treatment of early lung cancer. METHODS: Six patients were analyzed, including 4 squamous cell carcinoma, 1 adenocarcinoma, and 1 small cell lung cancer. TPS software was used to calculate the therapeutic dose amount of particles implanted, and the spacing and distribution of seeds in the target area and adjacent tissues. Under the guidance of CT, 20–55 particles were implanted at each site, with the total number of radioactive particles being 226, the particle spacing being 0.5–1.0 cm, and the implantation being performed in accordance with the principle of uniform implantation. The patients were each followed up with repeated pulmonary CT scans at 1, 3, 6, 12, 18, 24, 30 and 36 months after the procedure. In accordance with the response evaluation criteria in solid tumors (RECIST), the following definitions for responses were used: complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD). RESULTS: There were 2 CRs and 4 PRs one month after procedure; six patients were followed up 3 months after procedure, including 2 CRs and 4 PRs; one patient was lost in follow-up, and 5 patients were followed up 6 months after procedure, including 3 CRs and 2 PRs; five patients were followed up 12 months after procedure, including 3 CRs, 1 PR and 1 PD. The single PD patient was again given CT-guided implantation of (125)I radioactive particles for the treatment of recurrent lesions. The pulmonary CT was repeated 6 months after procedure, and the response was evaluated as SD. Four patients were followed up 18 months after procedure, including 3 CRs and 1 PR; one patient was lost in follow-up and 3 patients were followed up 24 months after the procedure with the response being evaluated as CR for all of them; one patient was followed up 36 months after procedure, and the response was evaluated as PD. During the follow-up, no serious complications occurred in any of the patients. CONCLUSIONS: The preliminary clinical observation showed that (125)I radioactive particle implantation was a safe, reliable and effective therapeutic method for early lung cancer. AME Publishing Company 2020-10 /pmc/articles/PMC7656391/ /pubmed/33209432 http://dx.doi.org/10.21037/jtd-20-2666 Text en 2020 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Yang, Dong-Yong
Lin, Yan-Ping
Xue, Cheng
Fan, Ji-Min
Wang, Yi
Cai, Chi
Song, Duan-Hong
Zeng, Yi-Ming
CT-guided percutaneous implantation of (125)I particles in treatment of early lung cancer
title CT-guided percutaneous implantation of (125)I particles in treatment of early lung cancer
title_full CT-guided percutaneous implantation of (125)I particles in treatment of early lung cancer
title_fullStr CT-guided percutaneous implantation of (125)I particles in treatment of early lung cancer
title_full_unstemmed CT-guided percutaneous implantation of (125)I particles in treatment of early lung cancer
title_short CT-guided percutaneous implantation of (125)I particles in treatment of early lung cancer
title_sort ct-guided percutaneous implantation of (125)i particles in treatment of early lung cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656391/
https://www.ncbi.nlm.nih.gov/pubmed/33209432
http://dx.doi.org/10.21037/jtd-20-2666
work_keys_str_mv AT yangdongyong ctguidedpercutaneousimplantationof125iparticlesintreatmentofearlylungcancer
AT linyanping ctguidedpercutaneousimplantationof125iparticlesintreatmentofearlylungcancer
AT xuecheng ctguidedpercutaneousimplantationof125iparticlesintreatmentofearlylungcancer
AT fanjimin ctguidedpercutaneousimplantationof125iparticlesintreatmentofearlylungcancer
AT wangyi ctguidedpercutaneousimplantationof125iparticlesintreatmentofearlylungcancer
AT caichi ctguidedpercutaneousimplantationof125iparticlesintreatmentofearlylungcancer
AT songduanhong ctguidedpercutaneousimplantationof125iparticlesintreatmentofearlylungcancer
AT zengyiming ctguidedpercutaneousimplantationof125iparticlesintreatmentofearlylungcancer